

Complications of Inflammatory Myopathy: Lung Disease

Dana Ascherman, M.D.
Division of Rheumatology



Case

- 41 y.o. white male with hypertension and hypercholesterolemia:
- **3/20/01:** periorbital edema
- **3/27/01:** acute polyarthrititis treated with steroids
- **4/7/01:** dyspnea, fever
- **4/11/01:** admitted to outside hospital with abnormal chest radiograph and bilateral infiltrates
- **4/26/01:** worsening dyspnea; unresponsive to antibiotics and steroids and transferred to UPMC

Monte Inpatient

L

37/72



- **ROS:** no Raynauds, mild joint pain, no dysphagia or weight loss
- **Exam** (Post bronchoscopy and BAL/biopsy):
 - dyspneic male with O2 saturation 90% (100% O2 mask/nasal cannula); otherwise normal VS and afebrile
 - erythematous rash but no heliotrope or Gottron's sign
 - diffuse rales
 - no synovitis
 - normal muscle strength
- **Labs:** WBC=11.7; Hgb nl; renal normal; ANA negative; CPK=657
- **BAL/Biopsy:** organizing hyaline membranes; COP-like
- **EMG:** generalized myopathy

Diagnosis: Polymyositis

- **anti-Jo-1 antibody returned later as positive**
- **Anti-synthetase syndrome**

Treatment: pulse IV solumedrol; tacrolimus

Course:

- **pneumomediastinum**
- **No intubation necessary**
- **off O2**
- **prednisone tapered and tacrolimus continued**

Objectives

- **Types of Lung Involvement**
- **Diagnosis of Lung Disease**
- **Management of Lung Disease**

Lung Involvement

- **multiple forms of lung involvement in myositis**
- **“Extrinsic”**
 - weakness of respiratory muscles
 - aspiration (due to swallowing impairment)
 - opportunistic infection
 - congestive Heart Failure (rare)
 - pulmonary hypertension (rare)
- **“Intrinsic”**
 - **Interstitial Lung Disease (ILD)**

Lung Involvement

- **at least 30% IIM patients have ILD**
 - **most commonly involved extramuscular organ system**
- **Anti-Jo-1 Ab found in 50–75% IIM pts with ILD**
 - **strong association of ILD with all anti-synthetase Ab in myositis**
- **lung disease may precede muscle involvement**
- **significant contribution to morbidity/mortality**
 - **5 year survival with ILD ~70% (vs. ~ 85%)**
 - **likely depends on subtype of ILD**

No correlation between extent/severity of muscle or skin disease and activity of ILD

Lung Involvement: Symptoms

- **dyspnea with or without nonproductive cough**
- **no digital clubbing unlike idiopathic pulmonary fibrosis (IPF)**
- **pleuritis and pleural effusion are unusual (unlike SLE)**
- **variable presentation of ILD:**
 - **acute (ARDS) or subacute [Clawson, A&R, 1995]**
 - **chronic and more slowly progressive**
 - **asymptomatic (usually with basilar fibrosis)**


Objectives

- **Types of Lung Involvement**
- **Diagnosis of Lung Disease**
- **Management of Lung Disease**

Diagnosis

1. Clinical suspicion

2. Imaging




3. Pulmonary Function Tests (PFTs)

4. Biopsy—rule out alternative processes

Diagnosis: Autoantibodies

Anti-synthetases



Autoantibodies

<u>Antibody</u>	<u>Target</u>	<u>Subset</u>	<u>Phenotype</u>
Mi-2	NuRD	DM	Shawl, V-neck, Gottron's
CADM-140	MDA-5	DM	Amyopathic, ILD
SAE	SUMO	DM	ILD, dysphagia
MJ	NXP-2	JDM	Calcinosis, Ulceration
p155/140	TIF1-g	DM, JDM	Severe skin, malignancy
SRP	72, 54 kDa	PM	Severe/refractory myositis
p200/100	HMGCR	IMNM	Necrotizing myopathy
Jo-1	ARS	PM/DM	Anti-synthetase syndrome

Anti-synthetase Autoantibodies

Antibody	Antigen (tRNA synthetase)	Prevalence in IIM (%)
----------	------------------------------	--------------------------

Jo-1	histidyl	20-30
PL-7	threonyl	<5
PL-12	alanyl	<5
QJ	isoleucyl	<5
EJ	glycyl	<5
KS	asparaginylyl	<1
Tyr	tyrosyl	<1
Zo	phenylalanyl	<1

Myositis--Autoantibodies